Breast Cancer

Advocate in Action: Elyse Spatz Caplan – Living Beyond Breast Cancer
Mar
17
2012

Elyse Spatz Caplan, Director of Programs and Partnerships with Living Beyond Breast Cancer, discusses the organization in depth including their mission, the launch of the new website at LBBC.org and all of the various ways in which they disseminate information to women living with and beyond breast cancer. For more information on Living Beyond Breast […]

Read More
The Group Room at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
Jan
14
2012

The 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium was a huge success! We produced more than 20 interviews on topics ranging from the BOLERO-2 and CLEOPATRA trials (Jose Baselga) to medical economics (Eric Winer), breast cancer and the environment (Robert Hiatt), the treatment of young women with breast cancer (Ann Partridge), metastatic breast cancer […]

Read More
C. Kent Osborne, MD: Breast Cancer Treatment – A Year In Review
Jan
13
2012

  Dr. C. Kent Osborne, the co-director of the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), discusses breast cancer advances and treatment highlights over the past year. He highlights three areas which he thinks will be practice changing: the overall treatment of HER2-positive breast cancer, the findings from the BOLERO-2 trial and the use of […]

Read More
Jose Baselga, MD, PhD: BOLERO-2 Findings Confirm Efficacy of Everolimus Plus Exemestane
Jan
13
2012

  Dr. Jose Baselga discusses the exciting data for the HER2-negative breast cancer patient — the BOLERO-2 trial released at the CTRC-AACR 34th Annual San Antonio Breast Cancer Symposium. Dr. Baselga is the Chief of the Division of Hematology/Oncology, Associate Director of the Massachusetts General Hospital Cancer Center and a Professor, Department of Medicine, Harvard […]

Read More
Jose Baselga, MD, PhD: CLEOPATRA Pertuzumab Trial Increases Progression-Free Survival
Jan
13
2012

  Dr. Jose Baselga discusses the exciting data for the HER2-positive breast cancer patient — the CLEOPATRA trial released at the CTRC-AACR 34th Annual San Antonio Breast Cancer Symposium. Dr. Baselga is the Chief of the Division of Hematology/Oncology, Associate Director of the Massachusetts General Hospital Cancer Center and a Professor, Department of Medicine, Harvard […]

Read More
Eric P. Winer, MD: Endocrine Therapy For Breast Cancer – Looking Into the Future
Jan
13
2012

  Dr. Eric Winer presented one of the plenary sessions at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. His talk was on endocrine therapy and looking into the future. His prognosis asks the question: Why haven’t we done better? And he addresses, what he believes, are the three key issues. Dr. Winer is […]

Read More
Robert A. Hiatt, MD, PhD: Institute of Medicine Report (IOM) – Breast Cancer & the Environment
Jan
13
2012

  Dr. Robert A. Hiatt discusses the Institute of Medicine Report on Breast Cancer and the Environment: A Life-Course Approach, presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. The report urges a life-course approach to studying breast cancer because new information suggests that women and girls might be more susceptible to some […]

Read More
Julie R. Gralow, MD: SWOG SO226 Trial and Bisphosphonates Update
Jan
13
2012

Dr. Julie R. Gralow discusses the SWOG SO226 where postmenopausal women with metastatic breast cancer given first-line treatment of fulvestrant (Faslodex) and anastrozole (Arimidix) have a better progression-free survival (PFS) than those given anastrozole alone. She also gives an update on bisphosphonates and osteonecrosis of the jaw at the 34th Annual CTRC-AACR San Antonio Breast […]

Read More
Clifford A. Hudis, MD: What’s New With Chemotherapy Trials?
Jan
13
2012

  Dr. Clifford Hudis discusses what’s new with chemotherapy trials at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. He reviews eight posters from the conference that explored various chemotherapy-related questions. Dr. Hudis is the Chief, Breast Cancer Medicine Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill-Cornell Medical College […]

Read More
Clifford A. Hudis, MD: The Value of Progression-Free Survival (PFS)
Jan
13
2012

  Dr. Clifford Hudis, through his discussion of the trial showing bevacizumab (Avastin) slows metastatic breast cancer, he highlights the important topic of the value of progression-free survival (PFS). This interview was conducted at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. Dr. Hudis is the Chief, Breast Cancer Medicine Service at Memorial Sloan […]

Read More